Emerging Targeted Therapies in Hidradenitis Suppurativa: A Systematic Review of JAK ‐1, IL ‐1, and CXCR1 /2 Pathway‐Directed Therapies
Australasian Journal of Dermatology · 16.11.2026
DOI: 10.1111/ajd.70235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 16.11.2026. Verfasst von Jonathan Nakad und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Skin Hospital, Darlinghurst and Westmead, New South Wales, Australia. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that may remain inadequately controlled despite established biologic therapies. Emerging therapies targeting JAK‐1, IL‐1 and CXCR1/2 pathways have generated interest, but their efficacy and safety remain uncertain. This review aimed to evaluate the efficacy and safety of JAK‐1 inhibitors, IL‐1 pathway inhibitors, and CXCR1/2 pathway‐directed therapies in moderate–to–severe HS. Following PRISMA 2020, seven randomised controlled trials (RCTs) were synthesised. Meta‐analysis was restricted a priori to placebo‐controlled JAK‐1 inhibitor RCTs, pooling the risk ratios for Hidradenitis Suppurativa Clinical Response of at least 50% (HiSCR50) using random‐effects models (Paule–Mandel τ 2 ; Hartung–Knapp adjustment). IL‐1 and CXCR1/2 pathway findings were synthesised descriptively because of heterogeneity and small study numbers. Safety outcomes were also summarised descriptively. Across three JAK‐1 trials assessed at Weeks 8, 12 or 16, the pooled estimate favoured treatment but was not statistically significant (risk ratio [RR] 1.47; 95% confidence interval [CI] 0.95–2.27). IL‐1 pathway inhibitors demonstrated heterogeneous and imprecise effects. A single RCT of eltrekibart, which neutralises CXCR1/2 ligands, provided an early efficacy signal at Week 16 (RR 1.54; 95% CI 0.78–3.04), requiring confirmation. Safety findings were descriptive and constrained by inconsistent reporting and short blinded observation periods; they do not establish longer‐term safety. Among the included trials, JAK‐1 inhibition showed a consistent direction of effect, while IL‐1 and CXCR1/2 findings remained preliminary. Larger, longer‐duration trials and direct comparisons are needed to establish therapeutic positioning.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Skin Hospital, Darlinghurst and Westmead, New South Wales, Australia.
ORCID-Profile: Jonathan Nakad, Manisha Kumar, Cindy Kok, Tara Sholji
Zitieren
APA
Nakad, J., Kumar, M., Kok, C., Frew, J., & Sholji, T. (2026). Emerging Targeted Therapies in Hidradenitis Suppurativa: A Systematic Review of JAK ‐1, IL ‐1, and CXCR1 /2 Pathway‐Directed Therapies. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70235
Vancouver
Nakad J, Kumar M, Kok C, Frew J, Sholji T. Emerging Targeted Therapies in Hidradenitis Suppurativa: A Systematic Review of JAK ‐1, IL ‐1, and CXCR1 /2 Pathway‐Directed Therapies. Australasian Journal of Dermatology. 2026. doi:10.1111/ajd.70235
BibTeX
@article{Nakad2026,
author = {Nakad, Jonathan and Kumar, Manisha and Kok, Cindy and Frew, John and Sholji, Tara},
title = {Emerging Targeted Therapies in Hidradenitis Suppurativa: A Systematic Review of JAK ‐1, IL ‐1, and CXCR1 /2 Pathway‐Directed Therapies},
journal = {Australasian Journal of Dermatology},
year = {2026},
doi = {10.1111/ajd.70235}
}
EUVIMED